It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neurodevelopment: Copy number variants underlie cases of cerebral palsy
At least 23% of cerebral palsy has a genetic basis, due to either point mutations or large chromosomal abnormalities. Using sequence data from 186 unrelated patients, a team led by Mark Corbett from the University of Adelaide, Australia, searched the protein-coding portion of the genome for disease-causing duplications or deletions, types of mutations collectively known as copy number variants, or CNVs. The researchers singled out 7 pathogenic CNVs that they corroborated through microarray profiling and gene expression analyses. Using a zebrafish model, the researchers identified a new gene “PDCD6IP” associated with cerebral palsy and epilepsy. They also flagged another 14 CNVs that were likely pathogenic but could not be confirmed. The work highlights the need for comprehensive genetic testing to be considered early in the diagnosis of cerebral palsy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Robinson Research Institute & Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia
2 Data61, Commonwealth Scientific and Industrial Research Organisation, Ecosciences Precinct, Dutton Park, Brisbane, QLD, Australia
3 School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia
4 Department of Diagnostic Genomics, Queen Elizabeth II Medical Centre, PathWest, Nedlands, WA, Australia
5 Department of Diagnostic Genomics, Queen Elizabeth II Medical Centre, PathWest, Nedlands, WA, Australia; School of Biomedical Sciences, University of Western Australia, Perth, WA, Australia
6 Genetic Services of Western Australia, King Edward Memorial Hospital, Subiaco, WA, Australia
7 Genetics Unit, Universitat Pompeu Fabra, Barcelona, Spain; Hospital del Mar Research Institute (IMIM) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain; SA Clinical Genetics, Women’s and Children’s Hospital & University of Adelaide, Adelaide, South Australia, Australia; South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
8 Robinson Research Institute & Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia